Trending:
Central Nervous System
-
5 December 2018 News
Boehringer and Domain Therapeutics form CNS drug discovery alliance
Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.
-
30 November 2018 Comment
New Alzheimer’s disease vaccine holds immense promise
Alzheimer’s disease is a complex and poorly understood disorder that ultimately leads to neurodegeneration in patients afflicted with the disease.
-
30 November 2018 News
US scientists reveal new gene therapy for Parkinson’s disease
Scientists from Feinstein Institute for Medical Research in the US have revealed that a gene therapy called AAV2-GAD for Parkinson’s disease will create new brain circuits for motor function.
-
23 November 2018 News
EU approves Camurus’s Buvidal injections to treat opoid dependency
Swedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to treat opioid dependency in adults and teenagers from 16 years...
-
16 November 2018 News
AbbVie and Mission partner on Alzheimer’s and Parkinson’s drugs
AbbVie has collaborated with UK-based drug discovery firm Mission Therapeutics for research and preclinical development of potential therapies to treat Alzheimer’s disease and Parkinson’s disease.
-
8 November 2018 News
Study identifies potential use of cancer drug Ponatinib for CCM
A new study led by the Centenary Institute in Australia has demonstrated the use of cancer drug Ponatinib as a potential treatment for cerebral cavernous malformations (CCM) in young individuals.
-
20 September 2018 projects
Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).
-
16 March 2018 projects
Eisai’s New Oral Solid Dose Production Facility, Suzhou
Eisai China has built a new oral solid dose (OSD) production facility at its new Suzhou plant in China.
-
29 July 2013 projects
Dainippon Sumitomo Pharma’s Chemistry Research Building, Osaka
Dainippon Sumitomo Pharma (DSP) opened a new chemistry research building in Osaka, Japan, in June 2013.
-
9 August 2011 projects
Grindeks Ursodeoxycholic Acid Manufacturing Plant
Latvia-based Grindeks opened a new active pharmaceutical ingredient (API) manufacturing unit in Riga in June 2011.
